Figure 5 | Scientific Reports

Figure 5

From: Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences

Figure 5The alternative text for this image may have been generated using AI.

A sketch of therapeutic development for CCNE1 amplified malignancies. Cycle E overexpression due to CCNE1 amplification and concurrent mutant p53 due to TP53 mutation promote progression from the G1 phase into S phase, providing therapeutic opportunity through synthetic lethality, chemotherapy, targeted therapy and radiation to enhance mitotic catastrophe and apoptosis.

Back to article page